These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35326493)

  • 1. Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models.
    Yati S; Silathapanasakul A; Thakaeng C; Chanasakulniyom M; Songtawee N; Porntadavity S; Pothacharoen P; Pruksakorn D; Kongtawelert P; Yenchitsomanus PT; Chanmee T
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
    Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W
    J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
    Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
    Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
    Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients.
    Zhang J; Song Y; Ahn AR; Park HS; Park SH; Moon YJ; Kim KM; Jang KY
    Cells; 2024 Aug; 13(17):. PubMed ID: 39273017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
    Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
    Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
    Zheng B; Ren T; Huang Y; Guo W
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of Interleukin 21 Reduction in Osteosarcoma Patients Due to PD-1/PD-L1-Mediated Suppression of Follicular Helper T Cell Functionality.
    Gao W; Zhou J; Ji B
    DNA Cell Biol; 2017 Sep; 36(9):794-800. PubMed ID: 28650673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
    Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
    Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
    Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies.
    Liu J; Peng X; Yang S; Li X; Huang M; Wei S; Zhang S; He G; Zheng H; Fan Q; Yang L; Li H
    Cell Commun Signal; 2022 Jan; 20(1):14. PubMed ID: 35090497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
    J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
    He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
    Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
    Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
    Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
    Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
    Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
    Himes BT; Peterson TE; de Mooij T; Garcia LMC; Jung MY; Uhm S; Yan D; Tyson J; Jin-Lee HJ; Parney D; Abukhadra Y; Gustafson MP; Dietz AB; Johnson AJ; Dong H; Maus RL; Markovic S; Lucien F; Parney IF
    Neuro Oncol; 2020 Jul; 22(7):967-978. PubMed ID: 32080744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
    Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
    Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
    Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
    Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.